<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To determine the maximum-tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic profiles, and clinical activity of an oral formulation of <z:chebi fb="0" ids="2038">azacitidine</z:chebi> in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs), <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>), or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Patients received 1 cycle of subcutaneous (SC) <z:chebi fb="0" ids="2038">azacitidine</z:chebi> (75 mg/m2) on the first 7 days of cycle 1, followed by oral <z:chebi fb="0" ids="2038">azacitidine</z:chebi> daily (120 to 600 mg) on the first 7 days of each additional 28-day cycle </plain></SENT>
<SENT sid="2" pm="."><plain>Pharmacokinetic and pharmacodynamic profiles were evaluated during cycles 1 and 2 </plain></SENT>
<SENT sid="3" pm="."><plain>Adverse events and hematologic responses were recorded </plain></SENT>
<SENT sid="4" pm="."><plain>Cross-over to SC <z:chebi fb="0" ids="2038">azacitidine</z:chebi> was permitted for nonresponders who received â‰¥ 6 cycles of oral <z:chebi fb="0" ids="2038">azacitidine</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Overall, 41 patients received SC and oral <z:chebi fb="0" ids="2038">azacitidine</z:chebi> (MDSs, n = 29; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>, n = 4; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, n = 8) </plain></SENT>
<SENT sid="6" pm="."><plain>Dose-limiting toxicity (grade 3/4 <z:hpo ids='HP_0002014'>diarrhea</z:hpo>) occurred at the 600-mg dose and MTD was 480 mg </plain></SENT>
<SENT sid="7" pm="."><plain>Most common grade 3/4 adverse events were <z:hpo ids='HP_0002014'>diarrhea</z:hpo> (12.2%), <z:hpo ids='HP_0002018'>nausea</z:hpo> (7.3%), <z:hpo ids='HP_0002013'>vomiting</z:hpo> (7.3%), febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (19.5%), and <z:mp ids='MP_0002899'>fatigue</z:mp> (9.8%) </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="2038">Azacitidine</z:chebi> exposure increased with escalating oral doses </plain></SENT>
<SENT sid="9" pm="."><plain>Mean relative oral bioavailability ranged from 6.3% to 20% </plain></SENT>
<SENT sid="10" pm="."><plain>Oral and SC <z:chebi fb="0" ids="2038">azacitidine</z:chebi> decreased DNA methylation in blood, with maximum effect at day 15 of each cycle </plain></SENT>
<SENT sid="11" pm="."><plain>Hematologic responses occurred in patients with MDSs and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Overall response rate (i.e., complete remission, hematologic improvement, or RBC or platelet transfusion independence) was 35% in previously treated patients and 73% in previously untreated patients </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSION: Oral <z:chebi fb="0" ids="2038">azacitidine</z:chebi> was bioavailable and demonstrated biologic and clinical activity in patients with MDSs and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> </plain></SENT>
</text></document>